NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer's Disease

Comb Chem High Throughput Screen. 2023;26(12):2099-2112. doi: 10.2174/1386207325666220428112541.

Abstract

Alzheimer's disease (AD) is an increasingly common neurodegenerative disease that attracts the attention of researchers and medical community in order to develop new, safe and more effective drugs. Currently available drugs could only slow the AD progression and relieve the symptoms, in addition to being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists were reported to have the ability to block the glutamate-mediated excitotoxic activity being good therapeutic targets for several neurodegenerative diseases, including AD. Based on data obtained so far, this review provides an overview over the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects regarding the use of NMDA antagonists for AD, and lastly a key focus is also given on its use in precision medicine.

Keywords: Alzheimer’s disease; N-methyl D-aspartate (NMDA) receptors; neurodegeneration; precision medicine.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Humans
  • Memantine / pharmacology
  • Memantine / therapeutic use
  • N-Methylaspartate / therapeutic use
  • Neurodegenerative Diseases* / drug therapy
  • Receptors, N-Methyl-D-Aspartate / therapeutic use

Substances

  • Memantine
  • N-Methylaspartate
  • Receptors, N-Methyl-D-Aspartate